Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised to acquire a 31.161% stake in fellow Chinese firm Nanjing Nanda Pharmaceutical Co., Ltd for a consideration of RMB 149.57 million (USD 20.6 million). Aidea had previously secured a 19.9646% stake in Nanda Pharma in July 2022, along with a collaboration on urokinase preparations. Once the transaction is completed, Aidea’s holding in Nanda Pharma will rise to 51.1256%.
Nanda Pharma specializes in injectable urokinase and small molecule heparin sodium APIs, with the former holding a significant market share in China.- Flcube.com
